EMD Serono Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:EMD Serono Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014249
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
EMD Serono Inc (EMD), formerly Serono Inc, a subsidiary of Merck KGaA is a healthcare products provider that offers oncology products. The company offers neurology and immunology; metabolic endocrinology, fertility and oncology products. It offers neurology and immunology products to find new treatment options for drugs and combines approaches that target T- and B-cell biology; cytokines and chemokines pathways; and biology and repair mechanisms. The company offers clinical research and development services in areas of immuno-oncology; oncology, multiple sclerosis and immunology. It markets its products in the US and abroad. EMD is headquartered in Rockland, Massachusetts, the US.

EMD Serono Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
EMD Serono Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
EMD Serono Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
EMD Serono Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
EMD Serono Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
EMD Serono Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
EMD Serono Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
EMD Serono Enters into Agreement with University of Texas MD Anderson Cancer Center 10
EMD Serono Partners with MD Anderson 11
Aeterna Zentaris Enters into Agreement with EMD Serono 12
EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 13
KineMed Enters Into Agreement With EMD Serono To Identify Protein And Lipid Biomarkers 14
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 15
Licensing Agreements 16
EMD Serono Amends its Licensing Agreement with Mersana Therapeutics 16
EMD Serono Enters into Licensing Agreement with Sutro Biopharma 17
EMD Serono Inc – Key Competitors 18
EMD Serono Inc – Key Employees 19
EMD Serono Inc – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Corporate Communications 21
Oct 23, 2017: EMD Serono Appoints Robert Truckenmiller to Senior Vice President of Market Access & Customer Solutions 21
Jan 17, 2017: Richard R. Smith Joins EMD Serono as Senior Vice President and Head of US Fertility and Endocrinology 22
May 19, 2016: EMD Serono Supports Military Community By Providing Access to Fertility Care Through Focused Patient Assistance Programs 23
Government and Public Interest 24
Jul 06, 2016: EMD Serono Commits €1.5 million to the Grant for Fertility Innovation (GFI) for 2016/17 24
Product News 25
May 01, 2017: 13th Annual EMD Serono Specialty Digest Details Utilization and Clinical Management Trends 25
Other Significant Developments 26
Jun 30, 2016: Merck Welcomes ZEISS and Hamilton Thorne as New Members of the Global Fertility Alliance 26
May 02, 2016: EMD Serono Expands Biopharmaceutical R&D Facility in Billerica, MA to Accelerate Innovation 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
EMD Serono Inc, Pharmaceuticals & Healthcare, Key Facts 2
EMD Serono Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
EMD Serono Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
EMD Serono Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
EMD Serono Inc, Deals By Therapy Area, 2011 to YTD 2017 8
EMD Serono Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
EMD Serono Enters into Agreement with University of Texas MD Anderson Cancer Center 10
EMD Serono Partners with MD Anderson 11
Aeterna Zentaris Enters into Agreement with EMD Serono 12
EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 13
KineMed Enters Into Agreement With EMD Serono To Identify Protein And Lipid Biomarkers 14
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 15
EMD Serono Amends its Licensing Agreement with Mersana Therapeutics 16
EMD Serono Enters into Licensing Agreement with Sutro Biopharma 17
EMD Serono Inc, Key Competitors 18
EMD Serono Inc, Key Employees 19
EMD Serono Inc, Other Locations 20

★海外企業調査レポート[EMD Serono Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • nib Holdings Limited:企業の戦略・SWOT・財務情報
    nib Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary nib Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Centrica Plc (CNA):電力:M&Aディール及び事業提携情報
    Summary Centrica Plc (Centrica) is an integrated energy company. It carries out electricity generation through and combined cycle gas turbine (CCGT) power stations, and nuclear power plants through its stake in EDF Energy Nuclear Generation. Centrica secures and supply gas and electricity to homes a …
  • Karoon Gas Australia Ltd (KAR):企業の財務・戦略的SWOT分析
    Karoon Gas Australia Ltd (KAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • A.P. Eagers Limited:戦略・SWOT・企業財務分析
    A.P. Eagers Limited - Strategy, SWOT and Corporate Finance Report Summary A.P. Eagers Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Tektronix, Inc.:企業の戦略・SWOT・財務分析
    Tektronix, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tektronix, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Ortho-Clinical Diagnostics Inc-医療機器分野:企業M&A・提携分析
    Summary Ortho-Clinical Diagnostics Inc (OCD) a subsidiary of The Carlyle Group L.P., is a provider of in vitro diagnostic products and services. The company designs, develops, manufactures and distributes in-vitro diagnostic products. It serves clinical laboratories by providing comprehensive soluti …
  • Doosan Heavy Industries & Construction Co Ltd (034020)-エネルギー分野:企業M&A・提携分析
    Summary Doosan Heavy Industries & Construction Co., Ltd. (Doosan Heavy Industries), a subsidiary of Doosan Corporation, is a power plant equipment manufacturer. It offers integrated equipment and solutions for power and water plants. The company’s major products include boilers, generators, engines, …
  • The Bank Of East Asia, Limited:企業の戦略・SWOT・財務分析
    The Bank Of East Asia, Limited - Strategy, SWOT and Corporate Finance Report Summary The Bank Of East Asia, Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Sevion Therapeutics Inc (SVON)-製薬・医療分野:企業M&A・提携分析
    Summary Sevion Therapeutics Inc (Sevion), formerly Senesco Technologies, Inc. is a pharmaceutical company that discovers, develops and acquires product candidates for the treatment of cancer and immunological diseases. The company has developed protein nanocage system that allows delivery of nucleic …
  • Sino Gas & Energy Holdings Ltd (SEH):石油・ガス:M&Aディール及び事業提携情報
    Summary Sino Gas & Energy Holdings Ltd (Sino Gas), a subsidiary of MIE Holdings Corp, is an oil and gas company that explores and develops unconventional gas assets production sharing contracts. The company holds working interest in the Linxing PSC and the Sanjiaobei PSC projects. It has strategic A …
  • NGM Biopharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary NGM Biopharmaceuticals Inc (NGM Bio) is a clinical-stage biopharmaceutical company that develops pipeline of biological therapeutics for the treatment of cardio-metabolic, immuno-oncology, retinal and liver diseases. The company’s pipeline products include NGM282, NGM386, NGM395, NGM621, NGM …
  • Institute for Research in Immunology and Cancer-製薬・医療分野:企業M&A・提携分析
    Summary Institute for Research in Immunology and Cancer (IRICoR), a subsidiary of University of Montreal is a non-profit research institute that offers drug discovery and commercialization services. The institute offers discovery, development and commercialization of novel drugs in oncology. It has …
  • Crown Bioscience Inc (6554):医療機器:M&Aディール及び事業提携情報
    Summary Crown Bioscience Inc (Crown Bioscience) is a drug discovery company that provides drug discovery and development services. The company offers antibodies, proteins, cell lines, tumor samples, in vivo and in vitro research reagents. It offers services such as preclinical research services, onc …
  • Prognomix Inc:企業の製品パイプライン分析
    Summary Prognomix Inc (Prognomix) is a personalized medicine company that develops molecular diagnostic test for detection of risks to develop renal, ocular, cardiac, cerebral, vascular and other complications of diabetic disease. The company’s products include PGX IR01, PGx GR01, PGx CD01, PGx IR02 …
  • Vivimed Labs Ltd (VIVIMEDLAB):企業の財務・戦略的SWOT分析
    Vivimed Labs Ltd (VIVIMEDLAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Huneed Technologies:企業の戦略・SWOT・財務情報
    Huneed Technologies - Strategy, SWOT and Corporate Finance Report Summary Huneed Technologies - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • National Petrochemical Co (2002):企業の財務・戦略的SWOT分析
    Summary National Petrochemical Co (Petrochem), a subsidiary of Saudi Industrial Investment Group, is a petrochemical company that invests and develops petrochemical industry. The company provides activities such as development and establishment, operation, management and maintenance of petrochemical …
  • Ottogi Corporation:企業の戦略・SWOT・財務情報
    Ottogi Corporation - Strategy, SWOT and Corporate Finance Report Summary Ottogi Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Kellogg Co:企業の戦略・SWOT・財務情報
    Kellogg Co - Strategy, SWOT and Corporate Finance Report Summary Kellogg Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Salem Media Group, Inc.:企業の戦略・SWOT・財務分析
    Salem Media Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Salem Media Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆